Delivery Order SPE2DB20D3103-SPE2DB23FL8N1
- Not listed
- This federal contract award, valued at $2,271.36, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that runs through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division. The award, valued at $2,195.48, is for the delivery of 4565843570 YONSA 125 MG TABLET 120S. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and has an ultimate completion date of October 8, 2024. Amerisourcebergen, a major pharmaceutical distributor, has been awarded numerous federal contracts to supply a wide range...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The $2,195.48 firm fixed-price delivery order is for the supply of 120 tablets of the prescription medication YONSA (abiraterone acetate). This award is part of a larger Indefinite Delivery Contract (IDC) with AmerisourceBergen, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The award is for the delivery of YONSA 125 MG TABLET 120S, a pharmaceutical product. The contract is a firm-fixed-price delivery order with a ceiling value of $2,195.48 and a completion date of October 15, 2024. This award is not associated with a set-aside program. AmerisourceBergen holds several Indefinite Delivery Contracts (IDCs)...
- This federal contract award, valued at $1,195.55, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to supply a comprehensive range of pharmaceutical products...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00. The award, worth $10,685.92, is for the delivery of Inlyta 5 mg tablets. The contract has no set-aside designation, indicating full and open competition. As a major pharmaceutical distributor, Amerisourcebergen plays a critical role in supplying essential...
- This federal contract award, valued at $1,598.34, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range...
- This federal contract award, with a value of $1,081.92, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical...
- This federal contract award, valued at $1,376.25, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA, valued at up to $999,999,999.00, which runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of...
- This federal contract award, valued at $1,210.08, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB23FL8N1Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,195.48 firm fixed-price delivery order is for the supply of Yonsa 125 mg tablets. This award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. This contract award did not have a set-aside designation, indicating open competition. Amerisourcebergen's parent company is Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 12/9/22 |